| Literature DB >> 22148323 |
Kevin D Freeman-Cook1, Paul Amor, Scott Bader, Leanne M Buzon, Steven B Coffey, Jeffrey W Corbett, Kenneth J Dirico, Shawn D Doran, Richard L Elliott, William Esler, Angel Guzman-Perez, Kevin E Henegar, Janet A Houser, Christopher S Jones, Chris Limberakis, Katherine Loomis, Kirk McPherson, Sharad Murdande, Kendra L Nelson, Dennis Phillion, Betsy S Pierce, Wei Song, Eliot Sugarman, Susan Tapley, Meihua Tu, Zhengrong Zhao.
Abstract
This paper describes the design and synthesis of a novel series of dual inhibitors of acetyl-CoA carboxylase 1 and 2 (ACC1 and ACC2). Key findings include the discovery of an initial lead that was modestly potent and subsequent medicinal chemistry optimization with a focus on lipophilic efficiency (LipE) to balance overall druglike properties. Free-Wilson methodology provided a clear breakdown of the contributions of specific structural elements to the overall LipE, a rationale for prioritization of virtual compounds for synthesis, and a highly successful prediction of the LipE of the resulting analogues. Further preclinical assays, including in vivo malonyl-CoA reduction in both rat liver (ACC1) and rat muscle (ACC2), identified an advanced analogue that progressed to regulatory toxicity studies.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22148323 DOI: 10.1021/jm201503u
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446